Physician profile
Ranjan Sharma
NPI 1417005034
$1,581.13
in general payments reported to CMS, 2019-2025
15 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $67.59 · 2021: $56.51 · 2022: $200 · 2023: $34.96 · 2024: $232 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $751.31 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $155.10 | 2019-2025 | |
| Optinose US, INC. | $143.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $112.05 | 2019-2024 | Dupixent |
| Genzyme Corporation | $64.88 | 2019 | |
| Glaxosmithkline, LLC. | $56.97 | 2019-2020 | |
| Genentech USA, INC. | $53.17 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.25 | 2019 | |
| Organon LLC | $42.66 | 2025 | Vtama |
| Kaleo, INC. | $39.34 | 2019 | |
| Abbvie INC. | $36.21 | 2022-2023 | Rinvoq |
| Hikma Pharmaceuticals USA | $28.96 | 2022-2023 | Ryaltris |
| Incyte Corporation | $22.21 | 2021 | |
| Lilly USA, LLC | $13.47 | 2024 | Ebglyss |
| Teva Pharmaceuticals USA, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjan Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.